Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein GR, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad RI, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Jun 25. pii: clincanres.3944.2018. doi: 10.1158/1078-0432.CCR-18-3944. [Epub ahead of print]

PMID:
31239321
2.

Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy.

Schwab KS, Kristiansen G, Isaak A, Held SEA, Heine A, Brossart P.

Front Oncol. 2019 May 15;9:403. doi: 10.3389/fonc.2019.00403. eCollection 2019. No abstract available.

3.

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Abdel Saci, Callahan MK, Rosenberg J.

J Clin Oncol. 2019 Jul 1;37(19):1608-1616. doi: 10.1200/JCO.19.00538. Epub 2019 May 17.

PMID:
31100038
4.

EF24 Suppresses Cholangiocellular Carcinoma Progression, Inhibits STAT3 Phosphorylation, and Induces Apoptosis via ROS-Mediated Oxidative Stress.

Bisht S, Nolting J, Wenzel J, Brossart P, Feldmann G.

J Oncol. 2019 Mar 4;2019:8701824. doi: 10.1155/2019/8701824. eCollection 2019.

5.

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.

Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, Weber MM, Ahmadzadehfar H, Schreckenberger M, Miederer M, Essler M.

Clin Nucl Med. 2019 May;44(5):e329-e335. doi: 10.1097/RLU.0000000000002532.

PMID:
30932975
6.

Antibiotic resistant bacteria and resistance genes in biofilms in clinical wastewater networks.

Sib E, Voigt AM, Wilbring G, Schreiber C, Faerber HA, Skutlarek D, Parcina M, Mahn R, Wolf D, Brossart P, Geiser F, Engelhart S, Exner M, Bierbaum G, Schmithausen RM.

Int J Hyg Environ Health. 2019 May;222(4):655-662. doi: 10.1016/j.ijheh.2019.03.006. Epub 2019 Mar 21.

PMID:
30905579
7.

The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma.

Holderried TAW, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, Klobuch S, Kröger N, Apostolova P, Finke J, Zeiser R, Heinicke T, Bornhäuser M, von Bergwelt-Baildon M, Tischer J, Wolf D.

Bone Marrow Transplant. 2019 Mar 4. doi: 10.1038/s41409-019-0498-0. [Epub ahead of print]

PMID:
30833743
8.

The occurrence of antimicrobial substances in toilet, sink and shower drainpipes of clinical units: A neglected source of antibiotic residues.

Voigt AM, Faerber HA, Wilbring G, Skutlarek D, Felder C, Mahn R, Wolf D, Brossart P, Hornung T, Engelhart S, Exner M, Schmithausen RM.

Int J Hyg Environ Health. 2019 Apr;222(3):455-467. doi: 10.1016/j.ijheh.2018.12.013. Epub 2019 Jan 6.

PMID:
30622005
9.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.

Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4.

10.

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.

Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-Martin JL, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kroger N.

Biol Blood Marrow Transplant. 2019 Mar;25(3):522-528. doi: 10.1016/j.bbmt.2018.10.017. Epub 2018 Nov 5.

PMID:
30408564
11.

Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.

Bisht S, Brossart P, Feldmann G.

Oncol Res Treat. 2018;41(10):590-594. doi: 10.1159/000493868. Epub 2018 Sep 28.

PMID:
30286472
12.

'Diseases Desperate Grown by Desperate Appliance Are Relieved, or Not at all' - Towards Finding a Cure for Pancreatic Cancer, Where Do We Stand Today?

Feldmann G, Brossart P, Maitra A.

Oncol Res Treat. 2018;41(10):588-589. doi: 10.1159/000493023. Epub 2018 Sep 28. No abstract available.

13.

[Survey of physicians on dealing with the topic "Tobacco consumption in patients with lung cancer"].

Bleckwenn M, Kaluç A, Zipfel M, Schnakenberg R, Brossart P, Weckbecker K.

Dtsch Med Wochenschr. 2018 Aug;143(16):132-138. doi: 10.1055/a-0601-6191. Epub 2018 Aug 7. German.

PMID:
30086558
14.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. No abstract available.

PMID:
29959413
15.

The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.

Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Fimmers R, Essler M, Ahmadzadehfar H.

Clin Cancer Res. 2018 Oct 1;24(19):4672-4679. doi: 10.1158/1078-0432.CCR-18-0947. Epub 2018 Jun 27.

PMID:
29950352
16.

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab.

Schwab KS, Kristiansen G, Schild HH, Held SEA, Heine A, Brossart P.

Case Rep Oncol. 2018 Jan 4;11(1):17-20. doi: 10.1159/000485562. eCollection 2018 Jan-Apr.

17.

Murine hematopoietic stem cell reconstitution potential is maintained by osteopontin during aging.

Li J, Carrillo García C, Riedt T, Brandes M, Szczepanski S, Brossart P, Wagner W, Janzen V.

Sci Rep. 2018 Feb 12;8(1):2833. doi: 10.1038/s41598-018-21324-x.

18.

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.

Franzen A, Vogt TJ, Müller T, Dietrich J, Schröck A, Golletz C, Brossart P, Bootz F, Landsberg J, Kristiansen G, Dietrich D.

Oncotarget. 2017 Dec 7;9(1):641-650. doi: 10.18632/oncotarget.23080. eCollection 2018 Jan 2.

19.

Importance of whole-body imaging with complete coverage of hands and feet in alveolar rhabdomyosarcoma staging.

Scheer M, Dantonello T, Brossart P, Dilloo D, Schweigerer L, Feuchtgruber S, Sparber-Sauer M, Vokuhl C, Bielack SS, Klingebiel T, Koscielniak E, von Kalle T; Cooperative Weichteilsarkom Studiengruppe (CWS).

Pediatr Radiol. 2018 May;48(5):648-657. doi: 10.1007/s00247-017-4066-8. Epub 2018 Jan 24.

PMID:
29368010
20.

Intravesical cidofovir application in BK virus cystitis after allogeneic hematopoetic stem cell transplantation (HSCT) is safe and highly effective.

Mayer K, Schumacher M, Eis-Hübinger AM, Pietzonka S, Drosten C, Brossart P, Wolf D.

Bone Marrow Transplant. 2018 Apr;53(4):495-498. doi: 10.1038/s41409-017-0044-x. Epub 2018 Jan 12. No abstract available.

PMID:
29330387
21.

Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.

Nellessen CM, Janzen V, Mayer K, Giovannini G, Gembruch U, Brossart P, Merz WM.

Arch Gynecol Obstet. 2018 Feb;297(2):281-284. doi: 10.1007/s00404-017-4583-6. Epub 2017 Nov 6. Review.

PMID:
29110117
22.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).

Ann Hematol. 2017 Dec;96(12):1993-2003. doi: 10.1007/s00277-017-3150-3. Epub 2017 Oct 31.

23.

Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.

Heine A, Flores C, Gevensleben H, Diehl L, Heikenwalder M, Ringelhan M, Janssen KP, Nitsche U, Garbi N, Brossart P, Knolle PA, Kurts C, Höchst B.

Oncoimmunology. 2017 Jun 16;6(8):e1338995. doi: 10.1080/2162402X.2017.1338995. eCollection 2017.

24.

PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.

Müller T, Braun M, Dietrich D, Aktekin S, Höft S, Kristiansen G, Göke F, Schröck A, Brägelmann J, Held SAE, Bootz F, Brossart P.

Oncotarget. 2017 May 2;8(32):52889-52900. doi: 10.18632/oncotarget.17547. eCollection 2017 Aug 8.

25.

Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.

Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G.

J Urol. 2018 Feb;199(2):370-377. doi: 10.1016/j.juro.2017.08.079. Epub 2017 Aug 19.

PMID:
28827104
26.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

27.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
28.

Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways.

Kotthoff P, Heine A, Held SAE, Brossart P.

Sci Rep. 2017 Jul 3;7(1):4522. doi: 10.1038/s41598-017-04558-z.

29.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.

Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45.

30.

Generation and functional characterization of MDSC-like cells.

Heine A, Held SAE, Schulte-Schrepping J, Wolff JFA, Klee K, Ulas T, Schmacke NA, Daecke SN, Riethausen K, Schultze JL, Brossart P.

Oncoimmunology. 2017 Feb 23;6(4):e1295203. doi: 10.1080/2162402X.2017.1295203. eCollection 2017.

31.

MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation.

Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R.

Leukemia. 2017 Dec;31(12):2732-2741. doi: 10.1038/leu.2017.137. Epub 2017 May 9.

32.

Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer.

Lerbs T, Bisht S, Schölch S, Pecqueux M, Kristiansen G, Schneider M, Hofmann BT, Welsch T, Reissfelder C, Rahbari NN, Fritzmann J, Brossart P, Weitz J, Feldmann G, Kahlert C.

BMC Cancer. 2017 Apr 7;17(1):249. doi: 10.1186/s12885-017-3225-5.

33.

In vivo and In vitro Identification of Endocannabinoid Signaling in Periodontal Tissues and Their Potential Role in Local Pathophysiology.

Konermann A, Jäger A, Held SAE, Brossart P, Schmöle A.

Cell Mol Neurobiol. 2017 Nov;37(8):1511-1520. doi: 10.1007/s10571-017-0482-4. Epub 2017 Mar 14.

PMID:
28289947
34.

Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour.

Yordanova A, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H.

Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1207-1214. doi: 10.1007/s00259-017-3652-1. Epub 2017 Mar 1.

PMID:
28246882
35.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.

Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19.

PMID:
28138160
36.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; the German-Austrian AMLSG.

Leukemia. 2017 May;31(5):1217-1220. doi: 10.1038/leu.2017.22. Epub 2017 Jan 18. No abstract available.

37.

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.

von Mässenhausen A, Brägelmann J, Billig H, Thewes B, Queisser A, Vogel W, Kristiansen G, Schröck A, Bootz F, Brossart P, Kirfel J, Perner S.

Int J Mol Sci. 2016 Dec 22;18(1). pii: E7. doi: 10.3390/ijms18010007.

38.

[Progressive induration of the skin with rough papules].

Heinemann A, Wolf D, Brossart P, Rehkämper-Schäfer C, Bieber T, Wenzel J.

Hautarzt. 2017 Mar;68(3):243-245. doi: 10.1007/s00105-016-3910-3. German. No abstract available.

PMID:
27999870
39.

JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.

Klaeschen AS, Wolf D, Brossart P, Bieber T, Wenzel J.

Exp Dermatol. 2017 Aug;26(8):728-730. doi: 10.1111/exd.13253. Epub 2017 May 3.

PMID:
27892610
40.

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.

Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik VI, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

Ann Hematol. 2016 Dec;95(12):1931-1942. Epub 2016 Oct 3.

41.

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2282. doi: 10.1038/leu.2016.207. No abstract available.

PMID:
27804971
42.

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K.

Leukemia. 2016 Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4. No abstract available.

PMID:
27375010
43.

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2160-2168. doi: 10.1038/leu.2016.126. Epub 2016 May 3. Erratum in: Leukemia. 2016 Nov;30(11):2282.

PMID:
27137476
44.

The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling.

Li J, Riedt T, Goossens S, Carrillo García C, Szczepanski S, Brandes M, Pieters T, Dobrosch L, Gütgemann I, Farla N, Radaelli E, Hulpiau P, Mallela N, Fröhlich H, La Starza R, Matteucci C, Chen T, Brossart P, Mecucci C, Huylebroeck D, Haigh JJ, Janzen V.

Blood. 2017 Jan 26;129(4):460-472. doi: 10.1182/blood-2016-05-714659. Epub 2016 Sep 28.

45.

Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer.

Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.

Clin Cancer Res. 2017 Apr 1;23(7):1829-1840. doi: 10.1158/1078-0432.CCR-16-0094. Epub 2016 Sep 27.

46.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2016 Dec;101(12):e485-e487. Epub 2016 Aug 18. No abstract available.

47.

Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products.

Berens C, Heine A, Müller J, Held SA, Mayer K, Brossart P, Oldenburg J, Pötzsch B, Wolf D, Rühl H.

Cytotherapy. 2016 Oct;18(10):1325-31. doi: 10.1016/j.jcyt.2016.06.014. Epub 2016 Aug 1.

PMID:
27491794
48.

Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.

Rittig SM, Haentschel M, Weimer KJ, Heine A, Müller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P.

Oncoimmunology. 2015 Oct 29;5(5):e1108511. doi: 10.1080/2162402X.2015.1108511. eCollection 2016 May.

49.

Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia.

Schwab KS, Heine A, Weimann T, Kristiansen G, Brossart P.

Case Rep Oncol. 2016 Jun 27;9(2):373-8. doi: 10.1159/000447508. eCollection 2016 May-Aug.

50.

Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.

von Mässenhausen A, Sanders C, Brägelmann J, Konantz M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schröck A, Bootz F, Brossart P, Kirfel J, Lengerke C, Perner S.

Int J Cancer. 2016 Nov 15;139(10):2359-69. doi: 10.1002/ijc.30279. Epub 2016 Jul 30.

Supplemental Content

Loading ...
Support Center